Alzheimer's Drug Discovery Foundation ’s DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s Brain Health Assessment technology, ViewMind Atlas?. We are proud to announce that ViewMind Inc. has received a $1.4M investment from the DxA, reinforcing their commitment to advancing novel biomarkers, including digital health assessments. This partnership highlights ViewMind's innovative use of eye movement and pupillometry data to enable the early detection of neurological conditions and to monitor treatment impacts on brain health. This milestone underscores two fundamental aspects of our technology: ?? ViewMind Atlas? offers non-invasive, scalable, accurate, and repeatable evaluations of cognitive brain health, independent of cultural or educational differences. ?? The technology addresses a critical need for functional brain assessments that are affordable, precise, and accessible. Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF, says, “ViewMind’s assessment based on ocular phenotyping, has the potential to address a critical need for scalable, accurate, non-invasive, and affordable functional brain assessments. The ability to correlate assessment results with structural brain changes, diagnose Alzheimer’s early and monitor the impact of treatment would be very impactful for drug development and patient care”. Mark Edwards, CEO and Co-founder of ViewMind, says, “ViewMind is honored to receive investment and support from ADDF and DxA, along with access to their expert advisory network. Our mission is to establish ViewMind as the world’s most precise solution for functional and cognitive brain assessments—in essence, the first-ever precision brain meter for accurately measuring functional brain health”. #BrainHealth #CognitiveHealth #Alzheimers #DigitalHealth #NeurologicalDisorders #HealthTech #EyeTracking #InnovationInHealthcare #Biomarkers #PrecisionMedicine
Parabéns!
SIPI FUND- ZENTYNEL
1 个月Congratulations!!!